** Shares in Gubra GUBRA.CO surge 29% at market open after the Danish biotech company signed a licensing deal with AbbVie ABBV.N to develop an amylin analog for obesity treatment
** The partnership marks AbbVie's entrance into the obesity field, the companies say in a press release
** Terms of the deal include $305 million as an upfront payment to Gubra and $1.875 billion in potential milestones, they add
** Analysts at Van Lanschot Kempen view the terms as "attractive", saying they appear to be higher than the broker's valuation
** Kempen adds AbbVie is a good partner for Gubra, as it can accelerate mid- and late-stage development of the GUBamy amylin analog programme, while offering infrastructure for a commercial launch
** Gubra's shares were up 19% by 0824 GMT, on track for their best day ever
(Reporting by Vera Dvorakova)
((vera.dvorakova@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.